Valuation: BICYCL

Market Cap 25Cr 22Cr 21Cr 19Cr 36Cr 2.4TCr 36Cr 250.38Cr 97Cr 1.22TCr 94Cr 92Cr 3.92TCr P/E 2026 *
-1.37x
P/E 2027 * -1.52x
Enterprise Value -26Cr -23Cr -22Cr -20Cr -38Cr -2.54TCr -38Cr -264.91Cr -102.55Cr -1.29TCr -99Cr -97Cr -4.15TCr EV / Sales 2026 *
-15x
EV / Sales 2027 * -23.1x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 26Cr
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.61%+0.69%+36.36%+82.72% 6.01TCr
-2.54%-0.21%+6.34%+31.72% 4.82TCr
-3.02%-5.20%+27.94%+32.51% 4.43TCr
+0.31%+3.02%+348.95%+643.82% 4.4TCr
-1.96%-0.33%+7.04%+99.46% 4.16TCr
+3.32%+3.49%+11.18%+51.23% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-4.86%-10.66%-26.27%+330.06% 2.49TCr
Average -0.04%+1.97%+55.30%+154.28% 4.41TCr
Weighted average by Cap. +0.17%+1.83%+60.00%+145.78%

Financials

2026 *2027 *
Net sales 1.75Cr 1.56Cr 1.46Cr 1.33Cr 2.5Cr 168.81Cr 2.53Cr 18Cr 6.82Cr 86Cr 6.58Cr 6.44Cr 276.14Cr 66.89L 59.41L 55.56L 50.63L 95.31L 64Cr 96.62L 6.72Cr 2.6Cr 33Cr 2.51Cr 2.46Cr 105.34Cr
Net income -17Cr -15Cr -14Cr -13Cr -25Cr -1.66TCr -25Cr -172.89Cr -67Cr -843.66Cr -65Cr -63Cr -2.71TCr -18Cr -16Cr -15Cr -13Cr -25Cr -1.69TCr -25Cr -175.94Cr -68Cr -858.54Cr -66Cr -64Cr -2.76TCr
Net Debt -51Cr -46Cr -43Cr -39Cr -73Cr -4.94TCr -74Cr -515.29Cr -199.48Cr -2.51TCr -192.53Cr -188.36Cr -8.08TCr -40Cr -36Cr -34Cr -31Cr -57Cr -3.88TCr -58Cr -405.31Cr -156.9Cr -1.98TCr -151.44Cr -148.16Cr -6.35TCr
Logo BICYCL
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-